# A Six Week, Double-Blind Randomized, Efficacy and Safety, Sleep Lab Trial With Esmirtazapine (Org 50081) (P05707)

> **NCT00506389** · PHASE3 · COMPLETED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 419 (actual)

## Conditions studied

- Insomnia

## Interventions

- **DRUG:** Esmirtazapine
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT00506389
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-06-06
- **Primary completion:** 2008-02-13
- **Final completion:** 2008-02-13
- **Target enrollment:** 419 (ACTUAL)
- **Last updated:** 2018-10-02

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00506389

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00506389, "A Six Week, Double-Blind Randomized, Efficacy and Safety, Sleep Lab Trial With Esmirtazapine (Org 50081) (P05707)". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT00506389. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*